Ovarian cancer is the sixth most common cause of cancer-related death in Australian women and is the fifth most common cancer in women worldwide. It arises from the cells on the outside of the ovary; the germ cell type that arises from the cells which produce eggs; and the rare stromal type arising from supporting tissues within the ovary.

Cartherics Pty Ltd is developing and translating a novel, dual specific cytotoxic CAR-T cell immunotherapy for treatment of relapsed ovarian cancer.